诺华放射配体疗法药物派威妥®用于治疗转移性激素敏感性前列腺癌患者新适应症在中国获批

格隆汇
Aug 25
诺华公司8月25日宣布,国家药品监督管理局(NMPA)已批准放射配体疗法(RLT)药物派威妥®(镥[177Lu]特昔维匹肽注射液)与雄激素受体通路抑制剂(ARPI)联合治疗前列腺特异性膜抗原(PSMA)阳性转移性激素敏感性前列腺癌(mHSPC)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10